While all poly ADP-ribose polymerase (PARP) inhibitors improved progression-free survival, olaparib significantly extended overall survival (OS), making it a preferred option.

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement next-generation ...

“There was a real reason to think that dialling out PARP2 might make PARP inhibitors better tolerated ... better tolerated as a long-term treatment, which we know is going to be important.

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

Global Ovarian Cancer Drugs Market size is expected to be worth around USD 9,857 Mn by 2032 from USD 3061 Mn in 2023, growing at a CAGR of 14.3% ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Ac-satoreotide is a first-in-class Actinium-labelled somatostatin receptor 2 antagonist targeting extensive-stage Small Cell Lung Cancer or Merkel Cell Carcinoma ...